Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer

P. de Besi, V. C. Sileni, L. Salvagno, C. Tremolada, G. Cartei, V. Fosser, A. Paccagnella, A. Peracchia, M. Fiorentino

Research output: Contribution to journalArticle

Abstract

Forty patients with advanced squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, 5-FU (by continuous 5-day infusion), and allopurinol; 37 are evaluable for response. Thirteen remissions (35%) were obtained, including three complete and ten partial, with a median duration of 9 months. After chemotherapy, seven responding patients underwent a surgical procedure, which was radical in four. The most frequent side effects were nausea and vomiting. This regimen is effective and can be included in a multimodality approach.

Original languageEnglish
Pages (from-to)909-910
Number of pages2
JournalCancer Treatment Reports
Volume70
Issue number7
Publication statusPublished - 1986

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

de Besi, P., Sileni, V. C., Salvagno, L., Tremolada, C., Cartei, G., Fosser, V., Paccagnella, A., Peracchia, A., & Fiorentino, M. (1986). Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. Cancer Treatment Reports, 70(7), 909-910.